Ignite Creation Date:
2025-12-24 @ 4:23 PM
Ignite Modification Date:
2026-01-05 @ 6:36 PM
Study NCT ID:
NCT00475566
Status:
COMPLETED
Last Update Posted:
2011-03-10
First Post:
2007-05-16
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Safety and Efficacy Study of the Dynalink®-E Everolimus Eluting Peripheral Stent System
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D050197', 'term': 'Atherosclerosis'}, {'id': 'D016491', 'term': 'Peripheral Vascular Diseases'}], 'ancestors': [{'id': 'D001161', 'term': 'Arteriosclerosis'}, {'id': 'D001157', 'term': 'Arterial Occlusive Diseases'}, {'id': 'D014652', 'term': 'Vascular Diseases'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NON_RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 104}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2007-05'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2011-03', 'completionDateStruct': {'date': '2010-02', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2011-03-09', 'studyFirstSubmitDate': '2007-05-16', 'studyFirstSubmitQcDate': '2007-05-16', 'lastUpdatePostDateStruct': {'date': '2011-03-10', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2007-05-21', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2008-07', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'In-stent binary restenosis (>50% stenosis), as measured by duplex ultrasound', 'timeFrame': '6 months'}], 'secondaryOutcomes': [{'measure': 'Angiographic in-stent binary restenosis rate (>50%)', 'timeFrame': '12 months'}, {'measure': 'Angiographic mean in-stent late loss, in-stent mean minimum lumen diameter (MLD), percent diameter stenosis', 'timeFrame': '12 months'}, {'measure': 'Primary, and secondary patency', 'timeFrame': '1, 6, 12, 18 months, 2, 3, 4, 5 years'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'conditions': ['Atherosclerosis', 'Peripheral Vascular Disease']}, 'referencesModule': {'references': [{'pmid': '22051872', 'type': 'DERIVED', 'citation': 'Lammer J, Scheinert D, Vermassen F, Koppensteiner R, Hausegger KA, Schroe H, Menon RM, Schwartz LB. Pharmacokinetic analysis after implantation of everolimus-eluting self-expanding stents in the peripheral vasculature. J Vasc Surg. 2012 Feb;55(2):400-5. doi: 10.1016/j.jvs.2011.08.048. Epub 2011 Nov 1.'}, {'pmid': '21658885', 'type': 'DERIVED', 'citation': 'Lammer J, Bosiers M, Zeller T, Schillinger M, Boone E, Zaugg MJ, Verta P, Peng L, Gao X, Schwartz LB. First clinical trial of nitinol self-expanding everolimus-eluting stent implantation for peripheral arterial occlusive disease. J Vasc Surg. 2011 Aug;54(2):394-401. doi: 10.1016/j.jvs.2011.01.047. Epub 2011 Jun 12.'}]}, 'descriptionModule': {'briefSummary': 'The purpose of this first-in-man study is to evaluate the safety and performance of the Dynalink®-E everolimus eluting peripheral stent system for the treatment of patients with atherosclerotic de novo or restenotic native superficial femoral and proximal popliteal lesions.\n\nAbbott Vascular is ceasing data analysis of the STRIDES Clinical Trial after 2 years. The decision to discontinue the study is not related to any safety concern. The rationale for this proposal is based on the following considerations:\n\nThe performance of DYNALINK-E from STRIDES shows no device- or procedure-related deaths and no stent fractures, and the rate of additional revascularizations has been stable since approximately 14 months after the procedure.\n\nEvaluations of the bare metal nitinol DYNALINK and ABSOLUTE stents in the clinical literature show low rates of death, reintervention and stent fracture, which are consistent with STRIDES and demonstrate the safety of the nitinol stent platform of the DYNALINK-E.\n\nLong-term animal studies show no concerns with the drug or polymer coating of DYNALINK-E - everolimus tissue concentration drops below the quantifiable limit by approximately 17 months after implant, and vascular response to the coating is normal with widely patent lumens and struts incorporated into vessel tissue.\n\nThe safety and performance of the DYNALINK-E has been substantiated by its clinical and pre-clinical data, and by the clinical data of similar products. Given the demonstrated mechanical integrity of the stent along with the evidence of a healthy long-term vascular response, there is a reasonable expectation of continued low event rates.', 'detailedDescription': 'A prospective, Non-Randomized, Single-arm, Multi-center, Clinical Study to Evaluate the Safety and Performance of the Dynalink®-E, Everolimus Eluting Peripheral Stent System for the Treatment of Atherosclerotic de Novo or Restenotic Native Superficial Femoral and Proximal Popliteal Artery Lesions.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Rutherford Becker Category 2-5\n* Single de novo or restenotic lesion in the superficial femoral or proximal popliteal artery\n* Disease segment length 30-170 mm\n* \\>50% diameter stenosis or total occlusion\n* Target reference vessel diameter 4.3-7.3 mm\n\nExclusion Criteria:\n\n* Target lesion previously treated with stent or surgery\n* Rutherford Becker Category 0, 1, or 6\n* Immunosuppressive disorder or currently receiving immunosuppressive agents\n* Serum creatinine \\>2.5 mg/dl'}, 'identificationModule': {'nctId': 'NCT00475566', 'acronym': 'STRIDES', 'briefTitle': 'A Safety and Efficacy Study of the Dynalink®-E Everolimus Eluting Peripheral Stent System', 'organization': {'class': 'INDUSTRY', 'fullName': 'Abbott Medical Devices'}, 'officialTitle': 'A Study to Evaluate the Safety and Performance of the Dynalink®-E, Everolimus Eluting Peripheral Stent System for Treating Atherosclerotic de Novo or Restenotic Native Superficial Femoral and Proximal Popliteal Artery Lesions', 'orgStudyIdInfo': {'id': '06-103'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'OTHER', 'label': '1', 'description': 'This is a prospective, non-randomized, single-arm, multi-center study. A projected 100 patients will receive the stent(s) in this study at approximately 10-15 European sites. The primary objective is to evaluate the safety and performance of the Dynalink®-E everolimus eluting peripheral stent system for the treatment of patients with atherosclerotic de novo or restenotic native superficial femoral or proximal popliteal lesions.', 'interventionNames': ['Device: Dynalink®-E everolimus-eluting peripheral stent', 'Device: Dynalink®-E, everolimus-eluting peripheral stent']}], 'interventions': [{'name': 'Dynalink®-E everolimus-eluting peripheral stent', 'type': 'DEVICE', 'description': 'Stenting of atherosclerotic de novo or restenotic lesions (\\> 50% stenosis) in the native superficial femoral or proximal popliteal artery', 'armGroupLabels': ['1']}, {'name': 'Dynalink®-E, everolimus-eluting peripheral stent', 'type': 'DEVICE', 'description': 'Stenting of atherosclerotic de novo or restenotic lesions (\\> 50% stenosis) in the native superficial femoral or proximal popliteal artery', 'armGroupLabels': ['1']}]}, 'contactsLocationsModule': {'locations': [{'zip': '9020', 'city': 'Klagenfurt', 'country': 'Austria', 'facility': 'Landeskrankenhaus Klagenfurt', 'geoPoint': {'lat': 46.62472, 'lon': 14.30528}}, {'zip': '1090', 'city': 'Vienna', 'country': 'Austria', 'facility': 'Allgemeines Krankenhaus der Stadt Wien- AKH Wien', 'geoPoint': {'lat': 48.20849, 'lon': 16.37208}}, {'city': 'Dendermonde', 'country': 'Belgium', 'facility': 'Sint Blasius Hospital', 'geoPoint': {'lat': 51.02869, 'lon': 4.10106}}, {'zip': '3600', 'city': 'Ghent', 'country': 'Belgium', 'facility': 'ZOL St. Jan', 'geoPoint': {'lat': 51.05, 'lon': 3.71667}}, {'zip': '9000', 'city': 'Ghent', 'country': 'Belgium', 'facility': 'University Hospital', 'geoPoint': {'lat': 51.05, 'lon': 3.71667}}, {'zip': '79189', 'city': 'Bad Krozingen', 'country': 'Germany', 'facility': 'Herzzentrum Bad Krozingen', 'geoPoint': {'lat': 47.91667, 'lon': 7.7}}, {'zip': '13347', 'city': 'Berlin', 'country': 'Germany', 'facility': 'The Jewish Hospital Berlin', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'zip': '04289', 'city': 'Leipzig', 'country': 'Germany', 'facility': 'Herzzentrum Leipzig', 'geoPoint': {'lat': 51.33962, 'lon': 12.37129}}, {'zip': '72076', 'city': 'Tübingen', 'country': 'Germany', 'facility': 'University Hospital Tübingen', 'geoPoint': {'lat': 48.52266, 'lon': 9.05222}}, {'zip': '83013', 'city': 'Mercogliano', 'country': 'Italy', 'facility': 'Casa di Cura di Montevergine', 'geoPoint': {'lat': 40.92157, 'lon': 14.74491}}], 'overallOfficials': [{'name': 'Johannes Lammer, M.D.', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Allgemeines Krankenhaus der Stadt Wien'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Abbott Medical Devices', 'class': 'INDUSTRY'}, 'responsibleParty': {'oldNameTitle': 'Marie-Helene Bettiol', 'oldOrganization': 'Abbott Vascular'}}}}